Bionic Protein News Today

ABSCI Forms Research Collaboration with MerchAbsci will deploy its Bionic Protein™ non-standard amino acid technology to produce enzymes tailored to Merck’s biomanufacturing applications and receive an upfront and certain other milestone payments. Merck also has the option to nominate up to three targets and enter into a drug discovery collaboration agreement, and Absci would then be eligible to receive up to $610 million in upfront fees and milestone payments.

Drug and target discovery company Absci has signed a research collaboration with Merck to produce new enzymes and will use Drug Creation

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

By Colin Kellaher Shares of Absci Corp. surged more than 50% in premarket trading Friday after the drug and target discovery company said it formed a research collaboration potentially worth... | January 7, 2022

Find out about the company enjoying a more than 50% rise for its stock.

Absci Announces Research Collaboration with Merck Collaboration to leverage Abscis Deep Learning-Enabled Drug Creation™ and Bionic Protein™... | January 7, 2022

Absci and Merck entered a research and collaboration agreement via the Absci Integrated Drug Creation Platform.